ONCY
Oncolytics Biotech, Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
oncolytics biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. the company is conducting clinical studies using reolysin®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. oncolytics’ clinical program includes a number of human trials at a variety of stages including a phase iii trial in head and neck cancers. the company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.
Market Cap: 78.4 Million
Primary Exchange: NASDAQ
Website: oncolyticsbiotech.com
Shares Outstanding: 75.4 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.4439133946533087
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Ethical Flags
Longest drawdown: 913 trading days
From: 2018-06-07 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|